30.05.2024 International Scientific Journal "Science and Innovation". Series D. Volume 3 Issue 5
Abstract. This article presents an analysis of scientific studies on the development of left ventricular hypertrophy in the context of arterial hypertension. Arterial hypertension is a risk factor for the development of various cardiovascular complications. Key points discussed in the article include analysing the relationship between arterial hypertension and left ventricular hypertrophy. The research data also covers the study of left ventricular mass and left ventricular mass index in patients with arterial hypertension. The analysis highlights the importance of blood pressure control in preventing the development of cardiovascular disease
Keywords: arterial hypertension, left ventricular hypertrophy, chronic heart failure, left ventricular mass, left ventricular mass index.
1. Ageev FT, Ovchinnikov AG. Left ventricular fi lling pressure: pathogenesis and ultrasonic assessment. Russian Heart Failure Journal. 2012;13(5):287-309. (in Russ.) DOI: 10.18087/rhfj .2012.5.1748 2. Ahmed S., Ungprasert P., Ratanapo S. Clinical characteristics of Takotsubo cardiomyopathy in North America. N Am J Med Sci 2013;5:77―81. 3. Andrikou E., Tsioufis C., Thomopoulos C. Left ventricular mass index as a predictor of new-onset microalbuminuria in hypertensive subjects: a prospective study. Am J Hypertens 2012;25(11):1195―1201. 4. Arai M., Matsui H., Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res. 1994;74:555—64. 5. Bang C.N., Greve A.M., Wachtell K., Kober L. Global systolic load, left ventricular hypertrophy, and atrial fibrillation. Am Heart J 2012;164(4):e13. 6. Barbieri A., Bursi F., Mantovani F. Left ventricular hypertrophy reclassification and death: application of the Recommendation of the American Society of Echocardiography/European Association of Echocardiography. Eur Heart J Cardiovasc Imaging 2012;13(1):109―117. 7. Barbieri A., Bursi F., Mantovani F. Prognostic impact of left ventricular mass severity according to the classification proposed by the American Society of Echocardiography/European Association of Echocardiography. J Am Soc Echocardiogr 2011;24(12):1383―1391. 8. Barsukov AV, Borisova EV, Didenko MV, Glebova SA, Airapetyan AV, Ligidov ML, Rud SD, Asaturova EI, Konovalova II. Left ventricular hypertrophy in terms of sudden cardiac death. Medicine: theory and practice (St. Petersburg). 2023; 8(3): 44-59. DOI: https://doi.org/10.56871/MTP.2023.95.29.005 9. Bluemke D.A., Kronmal R.A., Lima J.A. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008;52(25):2148―2155. 10. Codella N.C., Lee H.Y., Fieno D.S. Improved left ventricular mass quantification with partial voxel interpolation: in vivo and necropsy validation of a novel cardiac MRI segmentation algorithm. Circ Cardiovasc Imaging 2012;5:137―146. 11. Cuspidi C., Facchetti R., Sala C. Normal values of left-ventricular mass: echocardiographic findings from the PAMELA study. J Hypertens 2012;30(5):997―1003. 12. Cuspidi C., Sala C., Negri F. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens 2012;26(6):343―349. 13. Egamberdieva D.A., Karimdjanova G.A. Features of the course of chronic kidney disease in patients with atrial fibrillation // New day in medicine 1 (51) 2023, 104-111. 14. G.A. Karimdjanova, D.A. Egamberdieva. Study of clinical symptoms in patients with chronic obstructive disease and chronic heart failure depending on the presence of atrial fibrillation // Eurasian Paediatrics Journal 1 (16) 2023, 29-33. 15. Gerdts E., Okin P.M., Boman K. Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy. Am J Hypertens 2012;25(6):678―683. 16. Haywood L.J., Ford C.E., Crow R.S. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009;54(22):2023―2031. 17. Ho J.E., Lyass A., Lee D.S. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail 2013;6(2):279―286. 18. Katholi R.E., Couri D.M. Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens 2011;2011:495349. 19. Kawano H, Do Y, Kawano Y, Starnes V, Barr M, et al. Angiotensin II has multiple profi brotic eff ects in human cardiac fi broblast. Circulation. 2000;101:1130—7 20. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11—34. 21. Lang R.M., Bierig M., Devereux R.B. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7(2):79―108. 22. Larstorp A.C., Okin P.M., Devereux R.B. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study. Am J Hypertens 2012;25(10):1101―1109. 23. Lavie C., Milani R., Ventura H., Messerli F. Left ventricular geometry and mortality in patients >70 years of age with normal ejection fraction. // Am J Cardiol. – 2006. – V.98. – P.1396–9. DOI: 10.1016/j.amjcard.2006.06.037 24. Levy D, Garrison R, Savage D, Kannel WB, Castelli WP.. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham Heart Study. Ann Intern Med. 1989;110:101—7. 25. Maceira A.M., Mohiaddin R.H. Cardiovascular magnetic resonance in systemic hypertension. J Cardiovasc Magn Reson 2012;14:28. 26. Macfarlane P.W., Murray H., Sattar N. The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace 2011;13(5):634―639. 27. Mazzaro Cdo L., Costa Fde A., Bombig M.T. Ventricular mass and electrocardiographic criteria of hypertrophy: evaluation of new score. Arq Bras Cardiol 2008;90(4):227―231. 28. Okin P.M., Devereux R.B., Jern S. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292(19):2343―2349. 29. Okin P.M., Wachtell K., Devereux R.B. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006;296(10):1242―1248. 30. Okura T., Higaki J. Onset of atrial fibrillation and hypertensive treatment. Nihon Rinsho 2013;71(1):167―173. 31. Ozhereleva M.V., Ovchinnikov A.G. Special aspects of remodeling of the left ventricle in hypertensive disease. Medical Herald of the South of Russia. 2017;8(4):14-22. (In Russ.) DOI 10.21886/2219-8075-2017-8-4-14-22 32. Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, et al. Eff ect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation. 2001;103:102—7. 33. Parsai C., O’Hanlon R., Prasad S.K., Mohiaddin R.H. Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson 2012;14:54. 34. Pewsner D., Jüni P., Egger M. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ 2007;335(7622):711. 35. Pierdomenico S.D., Lapenna D., Cuccurullo F. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens 2008;21(4):464―470. 36. Pugliese NR, DE Biase N, Balletti A, Filidei F, Pieroni A, D'Angelo G, Armenia S, Mazzola M, Gargani L, Del Punta L, Asomov M, Cerri E, Franzoni F, Nesti L, Mengozzi A, Paneni F, Masi S. Characterization of hemodynamic and metabolic abnormalities in the heart failure spectrum: the role of combined cardiopulmonary and exercise echocardiography stress test. Minerva Cardiol Angiol. 2022 Jun;70(3):370-384. doi: 10.23736/S2724-5683.21.05743-4. Epub 2021 Jun 17. PMID: 34137244. 37. Ravera M., Noberasco G., Signori A. Left-ventricular hypertrophy and renal outcome in hypertensive patients in primary-care. Am J Hypertens 2013;26(5):700―707. 38. Schwartzenberg S, Redfi eld MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Eff ects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442–51. doi: 10.1016/j. jacc.2011.09.062 39. Sundstrom J., Lind L., Arnlov J. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 2001;103:2346―2351. 40. Verdecchia .P, Porcellati C., Reboldi G. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001;104(17):2039―2044. 41. Verdecchia P. Cardiac failure in hypertensive cardiopathy. Ital Heart J 2000;1(Suppl 2):72―77. 42. Verdecchia P., Angeli F., Borgioni C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16(11 Pt 1):895―899 43. Verdecchia P., Schillaci G., Borgioni C. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J Am Coll Cardiol 1998;31:383―390.
SCIENCE & INNOVATION